Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 4 art units • 8 examiners • 0 of 9 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Codexis Inc. has 9 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 8 distinct examiners and 4 distinct art units, indicating substantial examiner dispersion but more limited art-unit dispersion.
MEAH, MOHAMMAD Y is the busiest examiner, with 2 pending matters. The art-unit pattern supports coordination around recurring technical-group issues, while the examiner distribution still requires matter-level response planning.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (33%) |
| §112 only | 1 (11%) |
| Double-patenting only | 1 (11%) |
| Double-patenting + other | 3 (33%) |
| No statute on record | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEAH, MOHAMMAD Y | 2 | 70.7% | +42.8% |
| EPSTEIN, TODD MATTHEW | 1 | 60.8% | +43.6% |
| BOWERS, ERIN M | 1 | 54.7% | +9.8% |
| HUTSON, RICHARD G | 1 | 65.1% | +52.9% |
| ROBINSON, HOPE A | 1 | 67.7% | +43.0% |
| GRAY, JESSICA | 1 | 0.0% | +0.0% |
| JONES-FOSTER, ERICA NICOLE | 1 | 49.4% | +44.0% |
| NOAKES, SUZANNE MARIE | 1 | 73.4% | +18.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18660851 | RNA POLYMERASE VARIANTS | BOWERS, ERIN M | — |
| 18661523 | ENGINEERED RNA POLYMERASE VARIANTS | HUTSON, RICHARD G | — |
| 18395294 | ENGINEERED RNA LIGASE VARIANTS | GRAY, JESSICA | — |
| 18485925 | ENGINEERED 3-O-KINASE VARIANTS AND METHODS OF USE | NOAKES, SUZANNE MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18971755 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS | EPSTEIN, TODD MATTHEW | — |
| 18886292 | BIOCATALYSTS FOR EZETIMIBE SYNTHESIS | MEAH, MOHAMMAD Y | — |
| 18781007 | LOV-D ACYLTRANSFERASE MEDIATED ACYLATION | MEAH, MOHAMMAD Y | — |
| 18661523 | ENGINEERED RNA POLYMERASE VARIANTS | HUTSON, RICHARD G | — |
| 18638060 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | ROBINSON, HOPE A | — |
| 18516310 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | JONES-FOSTER, ERICA NICOLE | — |
| 18485925 | ENGINEERED 3-O-KINASE VARIANTS AND METHODS OF USE | NOAKES, SUZANNE MARIE | — |
| Art Unit | Apps |
|---|---|
| 1652 | 5 |
| 1656 | 2 |
| 1653 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18971755 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS | EPSTEIN, TODD MATTHEW | 1652 | Other | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18886292 | BIOCATALYSTS FOR EZETIMIBE SYNTHESIS | MEAH, MOHAMMAD Y | 1652 | §112DP | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18781007 | LOV-D ACYLTRANSFERASE MEDIATED ACYLATION | MEAH, MOHAMMAD Y | 1652 | DP | Non-Final OA | — | Pending | Jul 23, 2024 |
| 18660851 | RNA POLYMERASE VARIANTS | BOWERS, ERIN M | 1653 | §101§102 | Non-Final OA | — | Pending | May 10, 2024 |
| 18661523 | ENGINEERED RNA POLYMERASE VARIANTS | HUTSON, RICHARD G | 1652 | §101§102§103§112 | Non-Final OA | — | Pending | May 10, 2024 |
| 18638060 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | ROBINSON, HOPE A | 1652 | §112 | Non-Final OA | — | Pending | Apr 17, 2024 |
| 18395294 | ENGINEERED RNA LIGASE VARIANTS | GRAY, JESSICA | 1682 | §102§103DP | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18516310 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | JONES-FOSTER, ERICA NICOLE | 1656 | §102§103§112DP | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18485925 | ENGINEERED 3-O-KINASE VARIANTS AND METHODS OF USE | NOAKES, SUZANNE MARIE | 1656 | §101§102DP | Final Rejection | — | Pending | Oct 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCodexis Inc. has 9 pending office actions as of October 2026, spread across 4 art units and 8 examiners.
Mohammad Y Meah has the most, with 2 of Codexis Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
